Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

IMPORTANCE: Neuromyelitis optica (NMO) is an inflammatory disease of the optic nerves and spinal cord that leads to blindness and paralysis. Effective immunosuppression is the standard of care for relapse prevention. OBJECTIVE: To compare the relapse and treatment failure rates among patients receiv...

Bibliografski detalji
Glavni autori:	Mealy, M, Wingerchuk, D, Palace, J, Greenberg, B, Levy, M
Format:	Journal article
Jezik:	English
Izdano:	2014

Slični predmeti

Treatment of Neuromyelitis Optica: Review and Recommendations.
od: Kimbrough, D, i dr.
Izdano: (2012)

Treatment of neuromyelitis optica: Review and recommendations
od: Kimbrough, D, i dr.
Izdano: (2012)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
od: Tackley, G, i dr.
Izdano: (2016)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, i dr.
Izdano: (2012)

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
od: Levy M, i dr.
Izdano: (2021-08-01)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
od: Palace, J, i dr.
Izdano: (2010)

Seasonal pattern of variation in neuromyelitis optica relapses
od: Elsone, L, i dr.
Izdano: (2012)

A practical guide to the treatment of neuromyelitis optica.
od: Palace, J, i dr.
Izdano: (2012)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
od: Achim Berthele, i dr.
Izdano: (2023-04-01)

Prognosis of Relapsing Neuromyelitis Optica
od: J Gordon Millichap
Izdano: (2003-03-01)

Relapsing neuromyelitis optica spectrum disorder
od: M Lakshmi Lavanya, i dr.
Izdano: (2021-01-01)

The borderland of neuromyelitis optica.
od: Matthews, L, i dr.
Izdano: (2009)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
od: Sedani, S, i dr.
Izdano: (2012)

Racial differences in neuromyelitis optica spectrum disorder
od: Kim, S, i dr.
Izdano: (2018)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
od: Kitley, J, i dr.
Izdano: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
od: Kitley, J, i dr.
Izdano: (2014)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Pittock, S, i dr.
Izdano: (2019)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, i dr.
Izdano: (2011)

Treatment strategies for neuromyelitis optica
od: Tzu-Lun Huang, i dr.
Izdano: (2018-01-01)

Magnetic resonance imaging in neuromyelitis optica.
od: Tackley, G, i dr.
Izdano: (2014)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, i dr.
Izdano: (2015)

Observation of the efficacy of ofatumumab in the treatment of neuromyelitis optica spectrum disorders
od: ZHANG Rui, i dr.
Izdano: (2024-06-01)

Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
od: Bo Chen, i dr.
Izdano: (2017-04-01)

Advances in the long-term treatment of neuromyelitis optica spectrum disorder
od: Monique Anderson, i dr.
Izdano: (2024-01-01)

The evolving clinical spectrum of neuromyelitis optica
od: Viegas, S, i dr.
Izdano: (2008)

Clinical evaluation of rituximab treatment for neuromyelitis optica
od: M.J. Fernández-Megía, i dr.
Izdano: (2015-10-01)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i dr.
Izdano: (2014)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
od: Fujihara, K, i dr.
Izdano: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i dr.
Izdano: (2013)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
od: Waters, P, i dr.
Izdano: (2016)

Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder
od: Yi-Hong Liu, i dr.
Izdano: (2022-09-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
od: Collongues, N, i dr.
Izdano: (2013)

Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
od: Akiyuki Uzawa, i dr.
Izdano: (2011-01-01)

Seasonality of 278 neuromyelitis optica relapses in a Brazilian cohort
od: Denis Bernardi Bichuetti, i dr.
Izdano: (2015-02-01)

Review: Treatment of neuromyelitis optica: Current debate
od: Tomoko Okamoto, i dr.
Izdano: (2008-07-01)

Treatment of neuromyelitis optica: an evidence based review
od: Douglas Sato, i dr.
Izdano: (2012-01-01)

Current and future treatment approaches for neuromyelitis optica
od: Nicolas Collongues, i dr.
Izdano: (2011-03-01)

A mathematical model of cellular swelling in Neuromyelitis optica
od: Laranjeira, S, i dr.
Izdano: (2017)

Neuromyelitis Optica
od: Goyal V, i dr.
Izdano: (2009-10-01)

Neuromyelitis optica
od: Jacob Anu, i dr.
Izdano: (2007-01-01)